This study is a randomized controlled pilot trial designed to evaluate the effects and safety of a traditional Chinese medicine formula (DKD-1) as an add-on therapy to standard treatment in patients with Diabetic Kidney Disease (DKD). Eligible participants will be randomly assigned to receive either standard care alone or standard care combined with DKD-1 for 12 weeks. Kidney function, glycemic control, proteinuria, quality of life, and traditional Chinese medicine tongue features will be assessed before and after the intervention. The study aims to provide preliminary evidence on whether DKD-1 can improve renal function, glycemic control, and quality of life in this patient population.
Adults aged ≥18 years.
Patients diagnosed with type 2 diabetes mellitus and stage 3-4 chronic kidney disease (CKD), confirmed by a nephrologist and classified as ICD-10-CM codes E11.21-E11.29 combined with N18.3-N18.4, consistent with diabetic kidney disease (DKD) definitions.
Ability to understand the study procedures and provide written informed consent.
Willingness to comply with study procedures and follow-up visits.
Acute kidney injury or major kidney-related surgery within 3 months prior to enrollment.
Participation in another clinical trial within 3 months that may significantly affect renal function.
Alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal.
Pregnancy or breastfeeding.
Parallel
Chinese herbal formula DKD-1
Other interventionDKD-1 is a traditional Chinese herbal formula administered orally at a total daily dose of 14.5 g for 12 weeks. The formula consists of Astragalus membranaceus (3.0 g), Salvia miltiorrhiza (2.5 g), Chinese yam (2.5 g), Poria cocos (2.0 g), Moutan cortex (1.5 g), Schisandra chinensis (1.0 g), and Smilax glabra (2.0 g). It is used as an adjunct to standard care in patients with diabetic kidney disease.
Change in Estimated Glomerular Filtration Rate (eGFR)
Change in estimated glomerular filtration rate (eGFR) from baseline to week 12. eGFR is calculated using standard clinical laboratory methods. The primary endpoint is defined as the difference between eGFR at week 12 and baseline (ΔeGFR = eGFR\_12weeks - eGFR\_baseline).
Map coordinates are unavailable for these locations. Locations are shown below instead.
TaiwanClick on the lead sponsor to view all of their trials.
China Medical University Hospital
Lead sponsor
China Medical University Beigang Hospital
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
